Effects of Ropivacaine Concentrations on Prolonged Labor Analgesia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-14

Study Completion Date

2025-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With the changes in medical models and improvements in people's quality of life, parturients have higher demands for childbirth, making the alleviation and elimination of labor pain an important aspect of modern obstetrics. Intrathecal labor analgesia has been widely adopted in clinical practice to relieve pain. However, current studies mainly focus on parturients who are just beginning to receive labor analgesia, while for those experiencing prolonged analgesia, medical institutions still use traditional formulations, lacking relevant guidelines or expert consensus. In such cases, prolonged waiting and anxiety may lower the pain tolerance of parturients, leading to an increased need for higher concentrations of local anesthetics. To address this clinical gap, this study aims to explore the effects of different concentrations of ropivacaine in prolonged labor analgesia and has designed a prospective randomized controlled trial (RCT) to provide evidence for improving the analgesic regimen for this group of parturients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Association Between Epidural Labor Analgesia and Pregnancy Outcomes

NCT03381495

Labor Pain Pregnancy Outcomes Psychological Disorder

UNKNOWN NA

Effect of Epidural Analgesia on the Length of Labor and Delivery and Fetal Outcomes

NCT02396563

Labor Epidural Analgesia Nulliparous

UNKNOWN

Multicenter Study of Chloroprocaine Versus Ropivacaine for Epidural Labor Analgesia

NCT06472232

Obstetric Labor

NOT_YET_RECRUITING PHASE4

Ropivacaine and Fentanyl for Labor Epidural Initiation

NCT07076368

Pregnancy Labor and Delivery Labor Analgesia

RECRUITING PHASE3

Comparison of Two Methods of Administration of the Epidural, by Programmed Intermittent Bolus or Continuous Perfusion, on the Incidence of Cesarean Sections and Instrumented Deliveries in Primiparous Women

NCT02705872

First Child Delivery With Epidural

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

With changes in medical models and improvements in quality of life, parturients have higher expectations for childbirth, making the alleviation and elimination of labor pain an important aspect of modern obstetrics. Intrathecal labor analgesia is widely used in clinical practice to relieve labor pain. However, studies on prolonged labor analgesia, especially following the replacement of the first analgesic pump, are scarce. Medical institutions often continue to use traditional analgesic formulations without relevant guidelines or expert consensus. Prolonged analgesia may reduce pain tolerance in parturients, possibly necessitating adjustments in local anesthetic concentration to improve analgesic effectiveness. Given the clinical research gap, this study aims to explore the effects of different concentrations of ropivacaine on prolonged labor analgesia and its impact on maternal and neonatal safety.

Objective:

To investigate the effects and maternal-neonatal safety of using different concentrations of ropivacaine for prolonged labor analgesia, providing clinical evidence for optimizing labor analgesia regimens.

Methods:

This single-center prospective randomized controlled study will collect clinical data from parturients receiving labor analgesia at Chengdu Jinjiang District Maternal and Child Health Hospital from May to August 2025. Participants meeting the inclusion and exclusion criteria will be included. Following the replacement of the first analgesic pump, parturients will be randomly assigned to receive one of two ropivacaine concentration regimens (Group H: 0.12% ropivacaine; Group N: 0.1% ropivacaine). Data collection will include demographic information, pain scores, labor-related parameters, neonatal outcomes, and adverse reactions.

Interventions:

1. Group H: 0.12% ropivacaine + 0.5µg/ml sufentanil
2. Group N: 0.1% ropivacaine + 0.5µg/ml sufentanil Following the replacement of the first analgesic pump, parturients will receive the respective ropivacaine concentration formulation, with pain relief effects and labor-related indicators assessed at specified intervals.

Primary Outcome:

Pain scores at different time points (T0: at pump replacement; T1: 0.5 hours after pump replacement; T2: 1 hour after pump replacement; T3: at full cervical dilation or during transition to cesarean section).

Secondary Outcomes:

1. Labor-related indicators: Duration of first, second, and third stages of labor, blood loss, rate of instrumental delivery, mode of delivery (vaginal/cesarean).
2. Neonatal indicators: Neonatal weight, Apgar scores at 1 minute, 5 minutes, and 10 minutes.
3. Adverse reactions: Hypotension, nausea/vomiting, intrapartum fever (T≥38.0℃).

Hypothesis:

Different concentrations of ropivacaine for prolonged intrathecal labor analgesia will have varying effects on pain control and maternal-neonatal safety, with higher concentration ropivacaine (0.12%) likely being more effective in pain relief, while both concentrations are expected to show no significant difference in maternal and neonatal safety.

Ethics Approval:

This study has received approval from the ethics committee of Chengdu Jinjiang District Maternal and Child Health Hospital (Approval Number: 202312). All participants must sign an informed consent form to ensure the respect of participant rights and data confidentiality. The study will strictly adhere to relevant ethical standards and legal regulations to protect participant safety and privacy.

Funding:

This study is funded by the following projects:

1. Chengdu Medical Research Project (No. 2023465)
2. Chengdu Medical Research Project (No. 2022548)
3. Chengdu Medical Research Project (No. 2023304)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Labor Analgesia Prolonged Ropivacaine Concentration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

A double-blind design is a research method aimed at eliminating bias between participants and researchers. In this design, participants are randomly assigned to different intervention groups (such as different concentrations of ropivacaine), and neither the participants nor the researchers responsible for evaluating the results are aware of the specific group allocations. This ensures the objectivity and reliability of the research findings, avoiding the influence of subjective expectations or observational biases on data interpretation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

high concentration ropivacaine group

The combination of 0.12% ropivacaine and 0.5 μg/ml sufentanil

Group Type EXPERIMENTAL

High-concentration Ropivacaine

Intervention Type DRUG

After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.

Low concentration ropivacaine group.

The combination of 0.1% ropivacaine and 0.5 μg/ml sufentanil

Group Type ACTIVE_COMPARATOR

Low concentration ropivacaine group

Intervention Type DRUG

After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High-concentration Ropivacaine

After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.

Intervention Type DRUG

Low concentration ropivacaine group

After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ASA II
2. Age ≥ 18 years
3. Singleton pregnancy
4. No contraindications for epidural puncture and voluntarily accepting labor analgesia
5. Maternal participants changing the first pump fluid

Exclusion Criteria

1. Contraindications for epidural labor analgesia
2. Serious heart, brain, liver, or kidney diseases
3. Mental abnormalities
4. Neurological diseases
5. Maternal request for management of breakthrough pain before changing the pump fluid

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No